Supplementary Figures S1-S7 from MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors
Year: 2023
Type: supplementary-materials
Abstract: S1: RNAi data and CRISPR-Cas9 data divided by p53 status. S2: Expression of MDM2 and MDM4 in MRT and control cell lines. S3: CRISPR-Cas9 mediated inactivation of TP53 in MRT cell lines. S4: Immunoblots for p53 pathway activation upon MDM2 and MDM2/4 inhibition in MRT and control cell lines. S5: Cell counts, flow cytometry, and senescence assays in MRT cells following MDM2 and MDM2/4 inhibition. S6: Characterization of MRT cells expressing SMARCB1 or p16. S7: MRT xenograft growth characteristics and pharmacodynamic responses.
Authors: Thomas P. Howard, Taylor E. Arnoff, Melinda R. Song, Andrew O. Giacomelli, Xiaofeng Wang, Andrew L. Hong, Neekesh V. Dharia, Su Wang, Francisca Vazquez, Minh-Tam Pham, Ann M. Morgan, Franziska Wachter, Gregory H. Bird, Guillaume Kugener, Elaine M. Oberlick, Matthew G. Rees, Hong L. Tiv, Justin H. Hwang, Katherine H. Walsh, April Cook, John M. Krill-Burger, Aviad Tsherniak, Prafulla C. Gokhale, Peter J. Park, Kimberly Stegmaier, Loren D. Walensky, William C. Hahn, Charles W.M. Roberts
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361843017